Prevalence, Comorbidities, and Current Management of Chronic Spontaneous Urticaria in Japan: Retrospective Claims Database Study
The Journal of Dermatology · 2025-12 · 52 (12) · 1775-1787
DOI: 10.1111/1346-8138.17943 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Dermatology, online erschienen am 08.09.2025. Verfasst von Atsushi Fukunaga und 3 weiteren Autor:innen. Beteiligte Einrichtung: Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan. Hauptthemen laut MEDLINE: Chronic Urticaria, Histamine H1 Antagonists. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi K.K..
Abstract (Originalsprache)
Chronic spontaneous urticaria (CSU) affects 0.5%–1.0% of the population worldwide. However, information on the prevalence, comorbidities, and treatment patterns of CSU in Japan is limited. This observational study consisted of a cross‐sectional and longitudinal part. The prevalence and incidence of CSU were estimated using the JMDC claims database (JMDC Inc., Tokyo, Japan). CSU was defined as either ‘idiopathic urticaria’, ‘other urticaria’ or ‘unspecified urticaria’ based on ICD‐10 codes and prescribed H 1 ‐antihistamines for ≥ 6 weeks over a 3‐month period. Comorbidities, current treatments, and healthcare resource utilization in patients with CSU were also evaluated. The prevalence of CSU increased from 1.2% in 2016 to 1.6% in 2021 with a peak in children, while the incidence of CSU remained constant (0.7%–0.8%). Both prevalence and incidence were higher in females. Comorbid allergic rhinitis and conjunctivitis were frequent in the overall population, while comorbid asthma and atopic dermatitis were frequent in patients aged ≤ 11 years. During the 1‐year observational period, approximately 95% of patients used H 1 ‐antihistamines, followed by topical steroids, which are not recommended in the guidelines. Patients receiving the treatment in the same step as the initial month constituted the highest proportion represented during the following year. Oral corticosteroid use was relatively high, including in children, whereas omalizumab use was limited. The estimated recent prevalence and incidence of CSU in Japan were 1.6% and 0.8%, respectively. We also described patient characteristics and healthcare resource use. The present study encourages standardized practice for uncontrolled patients with CSU in Japan. Trial Registration: UMIN Clinical Trials Registry: UMIN‐CTR 000051032
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
- Sanofi K.K., Shinjuku, Tokyo, Japan.
ORCID-Profile: Atsushi Fukunaga, Kazuhiko Arima
Förderung
- Sanofi K.K.
Zitieren
APA
Fukunaga, A., Kishi, Y., Sunaga, Y., & Arima, K. (2025). Prevalence, Comorbidities, and Current Management of Chronic Spontaneous Urticaria in Japan: Retrospective Claims Database Study. The Journal of Dermatology, 52(12), 1775-1787. https://doi.org/10.1111/1346-8138.17943
Vancouver
Fukunaga A, Kishi Y, Sunaga Y, Arima K. Prevalence, Comorbidities, and Current Management of Chronic Spontaneous Urticaria in Japan: Retrospective Claims Database Study. The Journal of Dermatology. 2025;52(12):1775-1787. doi:10.1111/1346-8138.17943
BibTeX
@article{Fukunaga2025,
author = {Fukunaga, Atsushi and Kishi, Yuko and Sunaga, Yoshinori and Arima, Kazuhiko},
title = {Prevalence, Comorbidities, and Current Management of Chronic Spontaneous Urticaria in Japan: Retrospective Claims Database Study},
journal = {The Journal of Dermatology},
year = {2025},
volume = {52},
number = {12},
pages = {1775--1787},
doi = {10.1111/1346-8138.17943}
}
EUVIMED